Clinical Trial

A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves' Disease. In people with TED, the healthy tissue behind and around the eye becomes inflamed and swollen. One of the key symptoms of TED is proptosis (bulging eyes). The main goal of this trial is to learn whether treatment with Lu AG22515 improves proptosis in participants with moderate-to-severe TED.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-08-14; most recent amendment 2026-06-11.
Status change: Recruiting → Active, Not Recruiting 2026-01-13
Status change: Not Yet Recruiting → Recruiting 2024-10-11
Trial Details
NCT Number NCT06557850
Lead Sponsor H. Lundbeck A/S
Conditions Thyroid Eye Disease
Enrollment 20 participants
Start Date 2024-09-19
Primary Completion 2026-03-17 (estimated)
Study Completion 2026-09-29 (estimated)
Updated on ClinicalTrials.gov 2026-06-12